EUCTR2016-004159-56-IT进行中（未招募）1 期
Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blind, double - dummy, parallel group, placebo-controlled study (MERISUDD study) - Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II0 个研究点目标入组 820 人开始时间: 2021年5月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 820
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.In- or out-patients of both genders aged = 18 and = 75 years;
- •2.Patients with diverticular disease diagnosed by colonoscopy performed not before than 6 months before the enrolment in the study;
- •3.Patients with symptoms related to uncomplicated diverticular disease (i.e. abdominal pain, abdominal discomfort, bloating, flatulence) recurrent at least in the last six months;
- •Symptoms will be evaluated according to a structured questionnaire, based on a 5-point Likert scale, assessing frequency and based on a 10-point Likert scale, assessing severity. Patients will be considered eligible for the study when the abdominal pain total score (frequency plus severity) will be = 6 (independently of other gastrointestinal symptoms);
- •4.Written informed consent to participate in the study obtained according to GCP;
- •5.Patients able to comprehend the full nature and the purpose of the study, including possible risks and side effects, and able to cooperate with the Investigator and to comply with the requirements of the entire study (including ability to attend all the planned study visits according to the time limits), based on Investigator’s judgement;
- •6.Female subjects of childbearing potential (i.e., not permanently sterilised - post hysterectomy or tubal ligation status – or not postmenopausal) must be using an appropriate method of contraception according to the definition of Note 3 of ICH M3 Guideline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 410
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 410
排除标准
- •1.Patients with acute diverticulitis (both complicated and uncomplicated);
- •2.Patients with diverticular colitis;
- •3.Patients with solitary diverticulum of the colon;
- •4.Patients with active or recent peptic ulcer;
- •5.Patients with chronic liver, renal or hematologic diseases;
- •6.Patients with known allergy to salicylates;
- •7.Patients with previous major abdominal surgery;
- •8.Patients with concomitant colonic or extra colonic cancer or history of malignancy;
- •9.Patients with concomitant inflammatory bowel disease and celiac disease;
- •10.Use of antibiotics, probiotics and laxatives in the previous 4 weeks;
- •11.Use of non-steroidal anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid in the last 4 weeks before study entry and throughout the overall study period. Acetylsalicylic acid and paracetamol may be taken in the last 4 weeks before study entry and throughout the overall study period;
- •12.Patients with intended or ascertained pregnancy, lactation or women of childbearing age not using contraceptives;
- •13.Patients with recent history or suspicion of alcohol abuse or drug addiction;
- •14.Patients unable to give a valid informed consent or to properly follow the protocol procedures;
- •15.Concomitant participation in another study or participation in the evaluation of any investigational drugs/devices during 3 months before this study or previous participation in the same investigation;
- •16.The participation in the investigation is also not permitted to employees of the investigational site with direct involvement in the study or in other studies under the direction of that Investigator, as well as family members of the employees or the Investigator.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136
已完成
2 期
Mesalazine in chronic idiopathic urticariaChronic Idiopathic urticaria.Idiopathic UrticariaIRCT138710041520N1Shiraz University of Medical Sciences - Vice Chancellor for Research Affairs30
已完成
不适用
Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs).Patients with rheumatoid arthritis with anemia taking NSAIDsJPRN-UMIN000005362Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine13
尚未招募
不适用
The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)lcerative colitisJPRN-UMIN000009937AGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE60